NCT05014776 2026-02-24
Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
Clinical Trials
16 trialsNCT07368985 2026-01-27
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
Erasmus Medical Center
Phase 2 Not yet recruiting
NCT05273554 2026-01-12
A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05052723 2025-11-19
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Phase 2 Completed
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT04069273 2025-07-31
SEQUEL
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT03153410 2025-01-09
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT06532799 2024-11-12
BAH250
Essen Biotech
Phase 1/2 Recruiting
NCT05101356 2024-05-21
A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma
University of California, Davis
Phase 1/2 Recruiting
NCT03997448 2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT02918162 2024-02-15
Perioperative Chemo and Pembrolizumab in Gastric Cancer
Columbia University
Phase 2 Completed
NCT03488667 2023-05-19
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT04230954 2022-06-07
Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
University of South Alabama
Phase 2 Terminated
NCT03407976 2020-07-15
APPEASE
University of Utah
Phase 1 Terminated
NCT03634332 2019-05-07
Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC
Pancreatic Cancer Research Team
Phase 2 Unknown
NCT02943603 2018-07-13
A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach
University of Pittsburgh
Phase 2 Withdrawn